524711
VISTAPH
Start SIP
Invest Now
Start SIP in VISTAPH
Performance
- Low
- ₹8
- High
- ₹8
- 52 Week Low
- ₹8
- 52 Week High
- ₹13
- Open Price₹8
- Previous Close₹8
- Volume1,167
- 50 DMA₹8.60
- 100 DMA₹9.07
- 200 DMA₹9.79
Investment Returns
- Over 1 Month -3.5%
- Over 3 Month -19.27%
- Over 6 Month -27.01%
- Over 1 Year -21.57%
Smart Investing Starts Here Start SIP with Vista Pharmaceuticals for Steady Growth!
Vista Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- -7.4
- PEG Ratio
- 0.1
- Market Cap Cr
- 49
- P/B Ratio
- 1.1
- Average True Range
- 0.6
- EPS
- -
- Dividend Yield
- 0
- MACD Signal
- -0.08
- RSI
- 41.37
- MFI
- 30.8
Vista Pharmaceuticals Financials
Vista Pharmaceuticals Technicals
EMA & SMA
Current Price
₹8.00
-0.32
(-3.85%)
- Bearish Moving Average 16
- Bullish Moving Average 0
- 20 Day
- ₹8.34
- 50 Day
- ₹8.60
- 100 Day
- ₹9.07
- 200 Day
- ₹9.79
Resistance and Support
8.08
- R3 9.14
- R2 8.81
- R1 8.41
- S1 7.68
- S2 7.35
- S3 6.95
Vista Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2025-11-13 | Quarterly Results | |
| 2025-08-13 | Quarterly Results | |
| 2025-05-30 | Audited Results | |
| 2025-02-19 | Preferential Issue of shares & Others | Inter-alia, to consider 1. Notice of the EGM for the approval of raising of funds. 2. Other business matters. |
| 2025-02-12 | Quarterly Results |
Vista Pharmaceuticals F&O
About Vista Pharmaceuticals
- NSE Symbol
- VISTAPH
- BSE Symbol
- 524711
- Managing Director
- Mr. Murali Meraga
- ISIN
- INE427C01021
Similar Stocks to Vista Pharmaceuticals
Vista Pharmaceuticals FAQs
Vista Pharmaceuticals share price is ₹8 As on 23 January, 2026 | 03:19
The Market Cap of Vista Pharmaceuticals is ₹49.2 Cr As on 23 January, 2026 | 03:19
The P/E ratio of Vista Pharmaceuticals is -7.4 As on 23 January, 2026 | 03:19
The PB ratio of Vista Pharmaceuticals is 1.1 As on 23 January, 2026 | 03:19
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.